Barrett's esophagus future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Amresh Kumar (talk | contribs) |
Amresh Kumar (talk | contribs) |
||
Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
* Biomarkers | * Biomarkers | ||
# | # Can not be used to confirm the [[diagnosis]] of Barrett´s esophagus. | ||
# | # Can not be used to predict risk of progression. | ||
# | # Promising for the future<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>. | ||
* Endoscopic Therapy | * Endoscopic Therapy | ||
# | # In [[patients]] with confirmed high-grade [[dysplasia]] with Barrett' esophagus, it is more recommended to proceed with [[endoscopic]] eradication [[therapy]] with [[radiofrequency]] [[ablation]] ([[RFA]]), photodynamic [[therapy]] (PDT), or [[endoscopic]] [[mucosal]] [[resection]] (EMR) rather than surveillance. | ||
# | # In [[patients]] who have [[dysplasia]] in [[Barrett's esophagus]] associated with a visible [[mucosal]] irregularity it is recommended to proceed with [[endoscopic]] [[mucosal]] [[resection]] (EMR) to determine the T stage of the [[neoplasia]]<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>. | ||
==References== | ==References== |
Latest revision as of 21:50, 15 December 2017
Barrett's Esophagus Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Barrett's esophagus future or investigational therapies On the Web |
American Roentgen Ray Society Images of Barrett's esophagus future or investigational therapies |
FDA on Barrett's esophagus future or investigational therapies |
CDC on Barrett's esophagus future or investigational therapies |
Barrett's esophagus future or investigational therapies in the news |
Blogs on Barrett's esophagus future or investigational therapies |
Risk calculators and risk factors for Barrett's esophagus future or investigational therapies |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
- Biomarkers
- Can not be used to confirm the diagnosis of Barrett´s esophagus.
- Can not be used to predict risk of progression.
- Promising for the future[1].
- Endoscopic Therapy
- In patients with confirmed high-grade dysplasia with Barrett' esophagus, it is more recommended to proceed with endoscopic eradication therapy with radiofrequency ablation (RFA), photodynamic therapy (PDT), or endoscopic mucosal resection (EMR) rather than surveillance.
- In patients who have dysplasia in Barrett's esophagus associated with a visible mucosal irregularity it is recommended to proceed with endoscopic mucosal resection (EMR) to determine the T stage of the neoplasia[1].
References
- ↑ 1.0 1.1 Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. doi:10.1053/j.gastro.2011.01.030. PMID 21376940. Unknown parameter
|month=
ignored (help)